Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.64 (
MPP
)
1,876
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Aiming to decrease the acute side effects and genotoxic hazards of PUVA, pyrido (3,4-C) psoralen (PP) and 7-methyl pyrido (3,4-C) psoralen (
MPP
) were synthesized and studied. Their UVA maximum absorption lies at 325 and 330 nm, respectively. Their photostability is comparable to that of
8-MOP
. They complex to DNA in the dark, and, in the presence of UVA, produce only monoadditions to DNA, as shown by fluorescence and DNA denaturation-renaturation studies. In diploid eukaryotic yeast they are more effective than
8-MOP
for the induction of lethal effects and mitochondrial damage. Their mutagenic activity per unit dose of UVA is in the same range as that of
8-MOP
. However, per viable cell they are clearly less mutagenic than
8-MOP
. This difference is also observed for recombinogenic activity. No oxygen effect is observed. In mammalian cells the following ranges of effectiveness are found: inhibition of DNA synthesis in human fibroblasts:
MPP
greater than PP greater than
8-MOP
; mutagenic activity in V79 Chinese hamster cells:
MPP
greater than PP greater than
8-MOP
; cell transforming ability in C3H embryonic mouse cells:
MPP
greater than
8-MOP
greater than PP as a function of UVA dose, and:
8-MOP
greater than
MPP
greater than PP as a function of survival; induction of sister chromatic exchanges (SCE) per unit dose:
MPP
greater than PP greater than
8-MOP
in the linear part of the induction curve, and :
8-MOP
greater than PP greater than
MPP
at the maximum level of SCE obtained.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Photochemotherapy using pyridopsoralens. 389 94